Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy

Anna Østergaard; Cathrine Bohnstedt; Kathrine Grell; Matilda Degn; Bernward Zeller; Mervi Taskinen; Solveig Hafsteinsdottir; Helga Björgvinsdóttir; Mats Heyman; Peter Hoogerbrugge; Kjeld Schmiegelow; Nordic Society of Paediatric Haematology and Oncology (NOPHO)

doi:10.1038/s41375-020-0946-2

Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy

Anna Østergaard, Cathrine Bohnstedt, Kathrine Grell, Matilda Degn, Bernward Zeller, Mervi Taskinen, Solveig Hafsteinsdottir, Helga Björgvinsdóttir, Mats Heyman, Peter Hoogerbrugge, Kjeld Schmiegelow^*, Nordic Society of Paediatric Haematology and Oncology (NOPHO)

^*Corresponding author af dette arbejde

Afdeling for Børn og Unge

5 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	Leukemia
Vol/bind	35
Udgave nummer	3
Sider (fra-til)	863-866
Antal sider	4
ISSN	0887-6924
DOI	https://doi.org/10.1038/s41375-020-0946-2
Status	Udgivet - mar. 2021

Adgang til dokumentet

10.1038/s41375-020-0946-2

Andre filer og links

Link to publication in Scopus

Citationsformater

Østergaard, A., Bohnstedt, C., Grell, K., Degn, M., Zeller, B., Taskinen, M., Hafsteinsdottir, S., Björgvinsdóttir, H., Heyman, M., Hoogerbrugge, P., Schmiegelow, K., & Nordic Society of Paediatric Haematology and Oncology (NOPHO) (2021). Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy. Leukemia, 35(3), 863-866. https://doi.org/10.1038/s41375-020-0946-2

Østergaard, A, Bohnstedt, C, Grell, K, Degn, M, Zeller, B, Taskinen, M, Hafsteinsdottir, S, Björgvinsdóttir, H, Heyman, M, Hoogerbrugge, P, Schmiegelow, K & Nordic Society of Paediatric Haematology and Oncology (NOPHO) 2021, 'Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy', Leukemia, bind 35, nr. 3, s. 863-866. https://doi.org/10.1038/s41375-020-0946-2

@article{c9fa75818590416ca2cdec0582b37bc0,

title = "Acute lymphoblastic leukemia and down syndrome: 6-mercaptopurine and methotrexate metabolites during maintenance therapy",

keywords = "Adolescent, Antineoplastic Combined Chemotherapy Protocols/metabolism, Case-Control Studies, Child, Child, Preschool, Down Syndrome/drug therapy, Female, Follow-Up Studies, Humans, Infant, Maintenance Chemotherapy/mortality, Male, Mercaptopurine/administration & dosage, Methotrexate/administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy, Prognosis, Survival Rate",

author = "Anna {\O}stergaard and Cathrine Bohnstedt and Kathrine Grell and Matilda Degn and Bernward Zeller and Mervi Taskinen and Solveig Hafsteinsdottir and Helga Bj{\"o}rgvinsd{\'o}ttir and Mats Heyman and Peter Hoogerbrugge and Kjeld Schmiegelow and {Nordic Society of Paediatric Haematology and Oncology (NOPHO)}",

year = "2021",

month = mar,

doi = "10.1038/s41375-020-0946-2",

language = "English",

volume = "35",

pages = "863--866",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "3",

}

TY - JOUR

T1 - Acute lymphoblastic leukemia and down syndrome

T2 - 6-mercaptopurine and methotrexate metabolites during maintenance therapy

AU - Østergaard, Anna

AU - Bohnstedt, Cathrine

AU - Grell, Kathrine

AU - Degn, Matilda

AU - Zeller, Bernward

AU - Taskinen, Mervi

AU - Hafsteinsdottir, Solveig

AU - Björgvinsdóttir, Helga

AU - Heyman, Mats

AU - Hoogerbrugge, Peter

AU - Schmiegelow, Kjeld

AU - Nordic Society of Paediatric Haematology and Oncology (NOPHO)

PY - 2021/3

Y1 - 2021/3

KW - Adolescent

KW - Antineoplastic Combined Chemotherapy Protocols/metabolism

KW - Case-Control Studies

KW - Child

KW - Child, Preschool

KW - Down Syndrome/drug therapy

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Infant

KW - Maintenance Chemotherapy/mortality

KW - Male

KW - Mercaptopurine/administration & dosage

KW - Methotrexate/administration & dosage

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy

KW - Prognosis

KW - Survival Rate

UR - http://www.scopus.com/inward/record.url?scp=85087442484&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-0946-2

DO - 10.1038/s41375-020-0946-2

M3 - Letter

C2 - 32623444

SN - 0887-6924

VL - 35

SP - 863

EP - 866

JO - Leukemia

JF - Leukemia

IS - 3

ER -